News | July 05, 2007

Toshiba to Offer New PV-CTA Training Course

July, 6, 2007 – Toshiba America Medical Systems, Inc. announced a partnership with CVCTA Education to provide a Peripheral Vascular CTA (PV-CTA) training course in a move to strengthen its position in medical education and improved patient care.
This course will be the first of its kind to exceed current ACCF/AHA Level 2 requirements in the ACCF/AHA Clinical Competence Statement on Cardiac Imaging with Computed Tomography and Magnetic Resonance.
“PV-CTA is one of the most accurate and important non-invasive diagnostic tools available to detect PVD in patients reporting symptoms and in those who are asymptomatic,” said Doug Ryan, senior director, CT Business Unit. “Partnering with CVCTA Education to offer a comprehensive PV-CTA educational course is a step toward ensuring that PVD is properly detected and treated.”
The PV-CTA training course will be offered at CVCTA Training Centers in San Francisco, New York and Houston, several times per month with the first course starting in September. The course will use a blend of online learning and in-person training on Toshiba’s leading Aquilion CT scanners. Students will complete six hours of online didactics covering a review of anatomy and function, as well as findings and reporting. Also, in one day of hands-on workstation training, the students will be mentored on more than 25 cases of varying pathology. Students also will work on more than 75 cases via CVCTA’s proprietary MedMind CTA training software.
Created by Dr. Peter Fail from the Cardiovascular Institute of the South and Dr. Tony DeFrance from CVCTA, the PV-CTA course will provide students with more than 100 mentored cases with a wide variety of pathology, therefore exceeding the anticipated Level 2 requirements set by the ACCF and AHA. In total, the student will receive 40 hours of CME credit.
“PV-CTA will play an important role in helping imaging centers and hospitals educate the community on the emerging information and issues regarding the overall impact of PVD and the value of this diagnostic tool,” said Tony DeFrance, M.D., medical director of CVCTA Education.

For more information: www.medical.toshiba.com and www.cvcta.com

Related Content

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
Overlay Init